ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics
CL Arteaga, JA Engelman - Cancer cell, 2014 - cell.com
ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …
ago. Biomedical investigators have since developed substantial understanding of the …
Treatment of HER2-positive breast cancer: current status and future perspectives
CL Arteaga, MX Sliwkowski, CK Osborne… - Nature reviews Clinical …, 2012 - nature.com
The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …
with HER2-positive early stage breast cancer. However, a significant proportion of these …
HER3 in cancer: from the bench to the bedside
L Gandullo-Sánchez, A Ocaña, A Pandiella - Journal of Experimental & …, 2022 - Springer
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains
TJ Stuhlmiller, SM Miller, JS Zawistowski, K Nakamura… - Cell reports, 2015 - cell.com
Therapeutics that target ERBB2, such as lapatinib, often provide initial clinical benefit, but
resistance frequently develops. Adaptive responses leading to lapatinib resistance involve …
resistance frequently develops. Adaptive responses leading to lapatinib resistance involve …
Thirty years of HER3: from basic biology to therapeutic interventions
HM Haikala, PA Jänne - Clinical Cancer Research, 2021 - AACR
HER3 is a pseudokinase member of the EGFR family having a role in both tumor
progression and drug resistance. Although HER3 was discovered more than 30 years ago …
progression and drug resistance. Although HER3 was discovered more than 30 years ago …
[HTML][HTML] HER3 signaling and targeted therapy in cancer
ERBB family members including epidermal growth factor receptor (EGFR) also known as
HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in …
HER1, ERBB2/HER2/Neu, ERBB3/HER3 and ERBB4/HER4 are aberrantly activated in …
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Trastuzumab is a successful rationally designed ERBB2-targeted therapy. However, about
half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab …
half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab …
ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer
Resistance to HER2-targeted therapy represents a significant challenge for the successful
treatment of patients with breast cancer with HER2-positive tumors. Through a global mass …
treatment of patients with breast cancer with HER2-positive tumors. Through a global mass …
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
BN Rexer, CL Arteaga - Critical Reviews™ in Oncogenesis, 2012 - dl.begellhouse.com
Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-
oncogene, which confers a more aggressive tumor phenotype and associates with a poor …
oncogene, which confers a more aggressive tumor phenotype and associates with a poor …
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Objective To monitor trastuzumab resistance and determine the underlying mechanisms for
the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric …
the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric …